Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Heron Therapeutics reports strong sales growth and successful product launches

Heron Therapeutics showcased strong sales growth and successful product launches in Q4 2022.
While facing challenges such as delayed EU launch and regulatory concerns, the company is focused on strategic growth opportunities.
Opportunities to increase product uptake and drive market penetration through targeted strategies were discussed.
Overall, Heron Therapeutics remains optimistic about future updates and growth prospects.

Heron Therapeutics reports strong Q1 earnings amidst product challenges

Heron Therapeutics' Q1 2023 performance reflects revenue growth and a strategic focus on key products despite operational challenges.
The company's strengths in product innovation and market potential position it well for future growth opportunities.
Addressing challenges in product uptake and operational efficiency will be crucial for Heron Therapeutics to sustain its positive momentum.
By leveraging opportunities in product expansion and strategic realignment, the company can enhance profitability and drive long-term success.

Heron Therapeutics reports revenue growth and strategic financing for future

Heron Therapeutics delivered solid revenue growth in Q2 2023, driven by strong sales performance in its oncology portfolio and strategic financing activities.
While facing operating losses, the company remains focused on cost-saving initiatives, product growth, and maximizing asset value to drive future profitability.
Opportunities lie in upcoming product expansions, market acceptance of new launches, and strategic partnerships to fuel Heron Therapeutics' growth trajectory.
With a resilient financial position and a clear strategic direction, Heron Therapeutics is poised for future success in the competitive pharmaceutical landscape.

Heron Therapeutics cuts costs, boosts margins, eyes revenue growth

Heron Therapeutics demonstrated strong financial discipline with reduced operational expenses and improving gross margins. Record-high unit sales of key products and a clear commercial strategy position the company for revenue growth. While facing financial challenges and aiming for profitability, Heron Therapeutics remains optimistic about the growth potential of its key products.

Heron Therapeutics exceeds revenue expectations, eyes profitability by Q4 2024

Heron Therapeutics delivered robust financial results in Q4 2023, driven by strong oncology franchise performance and strategic partnerships. With a focus on innovation, cost efficiency, and revenue expansion, the company aims to achieve positive EBITDA by Q4 2024 and capitalize on market opportunities for sustained growth.

Heron Therapeutics excels in Q1, eyes profitability by 2024

Heron Therapeutics made notable progress in Q1 2024, with achievements in product performance, revenue growth, and profitability targets.
While facing challenges in EBITDA variability and regulatory compliance, the company is well-positioned to capitalize on growth opportunities.
By leveraging strengths in sales strategies, R&D focus, and financial efficiency, Heron Therapeutics aims for sustained success in the market.
Overall, the company's strategic initiatives and strong financial outlook signal a positive trajectory for future growth and market expansion.

Heron Therapeutics (HRTX) reports robust Q2 performance and strategic growth plans

Heron Therapeutics (HRTX) delivered strong financial performance with revenue growth, improved margins, and effective expense control in Q2 2024.
Despite challenges like potential competition and regulatory uncertainties, HRTX's strategic strengths in product portfolio and partnerships position it for future success.
Opportunities for growth through product expansions, partnerships, and expense management strategies highlight a positive outlook for HRTX in the competitive market.

Heron Therapeutics excels in Q3 with strong revenue growth and strategic advancements

Heron Therapeutics showcased robust financial performance, strategic partnerships, and product advancements in Q3 2024, positioning the company for sustained growth.
While facing challenges in operational efficiency and regulatory compliance, the company's strengths in innovation and market positioning offer avenues for continued success.
With a focus on expanding market presence, driving product adoption, and navigating regulatory landscapes, Heron Therapeutics is poised for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Heron Therapeutics (HRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

China Biologic Products Holdings

Galapagos

Illumina

Ionis Pharma

REGENXBIO

Ligand Pharmaceuticals

It's a good time to separate the weak from the strong. The post 7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio appeared first on InvestorPlace.

7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio

Heron's (HRTX) Zynrelef gains a marketing nod from the European Commission for managing postoperative pain in surgical wounds among adult patients. Stock rises.

Heron's (HRTX) Pain Drug Zynrelef Gets EU Approval, Shares Up

SAN DIEGO, Sept. 28, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the...

Heron Therapeutics Receives European Commission Authorization for ZYNRELEF™ (HTX-011) for the Treatment of Postoperative Pain

SAN DIEGO, Sept. 11, 2020 /PRNewswire/ -- Heron Therapeutics, Inc.

Heron Therapeutics to Present at Cantor Virtual Global Healthcare Conference

SAN DIEGO, Sept. 8, 2020 /PRNewswire/ -- Heron Therapeutics, Inc.

Heron Therapeutics Announces Successful Outcome of FDA Type A Meeting to Discuss HTX-011 for the Management of Postoperative Pain

Bargain hunters pounced on this beaten-down biotech stock last month. Here's why.

Why Heron Therapeutics Stock Popped in July

SAN DIEGO, Aug. 5, 2020 /PRNewswire/ -- Heron Therapeutics, Inc.

Heron Therapeutics Announces Financial Results for the Three and Six Months Ended  June 30, 2020 and Highlights Recent Corporate Updates

Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

Heron Therapeutics (HRTX) in Focus: Stock Moves 9% Higher

Heron's (HRTX) NDA seeking approval for pipeline candidate, HTX-011, for the management of postoperative pain gets CRL from the FDA, based on non-clinical issues. Shares down.

Heron's Pain Management Drug Gets Complete Response Letter

Its non-opioid painkiller gets a rejection over non-clinical issues.

Why Heron Therapeutics Stock Is Tanking Today

Investors need to pay close attention to Heron Therapeutics (HRTX) stock based on the movements in the options market lately.

Implied Volatility Surging for Heron Therapeutics (HRTX) Stock Options

SAN DIEGO, June 29, 2020 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it...

Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain

Novavax

Heron Therapeutics and Novavax are two key healthcare stocks to watch this month.

2 Top Healthcare Stocks to Watch in June

Heron Therapeutics (NASDAQ: HRTX) shares are trading higher on Wednesday after Guggenheim initiated coverage on the company's stock with a Buy rating and $24 price target.

Why Heron Therapeutics's Stock Is Trading Higher Today

AbbVie

Adverum Biotechnologies

AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.

3 Best Healthcare Stocks to Buy in May

Intercept Pharma

Heron Therapeutics and Intercept Pharmaceuticals are too cheap to ignore right now.

2 Dirt-Cheap Growth Stocks to Buy Now

Heron Therapeutics: Looking For Entry Following HTX-011 PDUFA Extension

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Heron Therapeutics (HRTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.8%

Heron Therapeutics is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Moving Average Crossover Alert: Heron Therapeutics

Akcea Therapeutics

AMAG Pharmaceuticals

Axsome Therapeutics

Cronos Group

Eidos Therapeutics Inc

Paratek Pharma

PolarityTE Inc

Viking Therapeutics

Intrexon

ZIOPHARM Oncology

Biotech investment is risk fraught. Most biotech stocks are at the mercy of binary events, which serve as make-or-break catalysts.

12 Biotech Stocks Primed For A Short Squeeze

As of late, it has definitely been a great time to be an investor in Heron Therapeutics, Inc. (HRTX).

Heron Therapeutics, Inc. (HRTX) Shares March Higher, Can It Continue?

Heron Therapeutics: Looking Solid Heading Into 2020

News for Heron Therapeutics Stock (HRTX)